1. Cost Effectiveness of Rescreening Cervicovaginal Smears
- Author
-
Raab Ss, N S Bishop, and Zaleski Ms
- Subjects
medicine.medical_specialty ,Cost effectiveness ,Cost-Benefit Analysis ,Cervical disease ,Sensitivity and Specificity ,Medical Records ,Uterine Cervical Diseases ,Analyse cout efficacite ,Life Expectancy ,Reference Values ,medicine ,Humans ,Vaginal Smears ,Gynecology ,business.industry ,Obstetrics ,Medical screening ,Health Care Costs ,General Medicine ,Models, Theoretical ,Cervix Diseases ,Cytopathology ,Female ,business ,Premalignant lesion ,Follow-Up Studies - Abstract
Although cytology laboratories are mandated to rescreen at least 10% of cervicovaginal smears, there is no uniform national rescreening practice. Follow-up data for 16,188 rescreened cervicovaginal smears were studied and decision analysis was performed to determine an optimal rescreening strategy. High-grade dysplasia was detected in 0.40% of women with a history of cervical disease and in 0.04% without a history of cervical disease. Compared with 0% rescreening of smears, with 15% rescreening the cost to gain a year of discounted life expectancy was $386,890 for women without a history of cervical disease, and $2,980 for women with a history of cervical disease. We conclude that rescreening only smears from women with a history of cervical disease could save US laboratories more than $11.2 million annually without seriously compromising care.
- Published
- 1999